ArticlePloS one2025
The impact of hyperglycemia on prognosis in chronic obstructive pulmonary disease patients with coronary heart disease: A five-year prospective study.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere is a lack of research on the impact of hyperglycemia on the prognosis of patients with both chronic obstructive pulmonary disease (COPD) and coronary heart disease (CHD). This study aims to investigate the effect of hyperglycemia on long-term acute exacerbation frequency and mortality rates in COPD patients with CHD.
methodsThis real-world and prospective study recruited inpatients with COPD from the second Xiangya Hospital of Central South University, in China in December 2016, with follow-up until March 2023. Moreover, we collected data on COPD participants from the National Health and Nutrition Examination Survey (NHANES), spanning the period from 1999 to 2018. All patients included in the study had concurrent CHD and available fasting blood glucose (FBG) measurements at the time of admission. Patients were categorized into normal blood glucose and hyperglycemia groups based on whether their FBG exceeded 7 mmol/L. Self-administered questionnaires, clinical records, and self-reported data were the primary methods for data collection. Kaplan-Meier survival analyses and Cox proportional hazard models were used to assess the risk of acute exacerbation and all-cause mortality for COPD patients with CHD during the follow-up period.
resultsAmong patients with both COPD and CHD, patients in the hyperglycemia group had lower smoking index, higher prevalence of diabetes, lower eosinophil percentage (Eos%), notably elevated C-reactive protein (CRP) and brain natriuretic peptide (BNP) levels, reduced albumin (ALB) levels, and higher incidence of fungal positivity than patients in the normal blood glucose group (p < 0.05). Age (HR = 1.098, 95% CI = 1.013-1.191, p = 0.024), hyperglycemia (HR = 3.622, 95% CI = 1.08-12.15, p = 0.037), and comorbidities with obsolete pulmonary tuberculosis (HR = 3.185, 95% CI = 1.03-9.85, p = 0.044) were identified as independent predictors of mortality in multivariate analyses over the follow-up years. Hyperglycemia, age, smoking, white blood cell count (WBC), uric acid (UA), creatinine (Cr), ALB, and aspartate aminotransferase (AST) were also identified as independent predictors of mortality in multivariate analyses during the follow-up years, according to NHANES data. Kaplan-Meier survival curves demonstrated that patients in the hyperglycemia group experienced significantly higher rates of exacerbations and mortality compared to those in the normal blood glucose group over a follow-up period of 5 years or more (log-rank test, p < 0.05).
conclusionsHyperglycemia serves as an independent risk factor for prolonged acute exacerbations and mortality in COPD patients complicated with CHD post-discharge. Proactive intervention strategies targeting hyperglycemia should be promptly instituted to mitigate the risk of future acute exacerbations and mortality in COPD patients with CHD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.